Latest Kaiser Health News Stories
Proposition 65 requires California businesses to label products and buildings with warnings about substances the state deems as toxic, ranging from aloe vera to asbestos. A state panel plans to debate whether to add acetaminophen, the active ingredient of common over-the-counter medications such as Tylenol, to the toxics list, raising questions about the value of these ubiquitous warnings.
Legislation that takes effect next July will let people buy the medications without a prescription for a limited period. Medical professionals say it’s a step in the right direction but will not significantly increase the use of the medicine without additional efforts.
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.”
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
Doctors are less likely to prescribe opioids in Germany and quicker to notice if a patient is at risk of abuse. And, for those who do experience addiction, treatment is easier to come by.
KHN’s Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.
A few hundred hospitals have banded together to sue drugmakers in state courts, but far more are staying on the sidelines to avoid ‘unflattering attention’ about their role in the opioid crisis.
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
The topic, which polls show is top of mind among voters, kept returning throughout the fourth debate of Democratic presidential candidates.
The Democratic presidential candidates have hit hard on health care, but generally the debates have centered on what kind of system candidates propose. The candidates’ ideas on many other issues, such as mental health and gun safety, have attracted much less attention.
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.
For more than a decade, customers used the online plan finder to compare dozens of policies. Yet after a redesign of the website, the search results no longer list which plan offers a customer the best value. Federal officials say it will be fixed before enrollment begins next week.